247-499-3

Applied Filters:

Keyword:'247-499-3'

Showing 1-3 of 3 results for "247-499-3" within Papers

Design of potent and selective inhibitors of myo-inositol 1,4,5-trisphosphate 5-phosphatase.

S T Safrany et al.

Biochemistry, 33(35), 10763-10769 (1994-09-06)

The interactions of synthetic analogues of D-myo-inositol 1,4,5-trisphosphate [Ins(1,4,5)P3] with the Ins(1,4,5)P3 receptor in permeabilized SH-SY5Y cells and with two key metabolic enzymes, Ins(1,4,5)P(3)3-kinase from a supernatant preparation of rat brain homogenates and Ins(1,4,5)P(3)5-phosphatase from human erythrocyte ghosts, have been

Preloading with atorvastatin before percutaneous coronary intervention in statin-naïve Asian patients with non-ST elevation acute coronary syndromes: A randomized study.

Yangsoo Jang et al.

Journal of cardiology, 63(5), 335-343 (2013-11-13)

Data on atorvastatin pretreatment in Asian patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) are limited. However, there have been studies in other populations in Asia which demonstrated that statins can reduce the risk of periprocedural myocardial

Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.

Lior H Katz et al.

The Cochrane database of systematic reviews, 9(9), CD008516-CD008516 (2012-09-14)

The standard length of peginterferon plus ribavirin treatment for chronic hepatitis C virus (HCV) genotype 1 infected patients is 48 weeks. However, the number of patients demonstrating a sustained virological response is not high. In order to improve sustained virological

Page 1 of 1